NEU-411 is a brain-penetrant, potent and selective inhibitor of LRRK2 for the treatment of Parkinson’s disease (PD). Initial findings will be presented in a poster titled, “A Phase 1 Study of ...

A team of scientists has revealed a breakthrough discovery, linking genetic variants in the gene ITSN1 to a significantly ...

The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces the selection of five high priority targets through its Targets to Therapies Initiative — a program aimed at expanding the ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

NAPCO Security Technologies, Inc. , one of the leading designers and manufacturers of high-tech electronic security devices, wireless recurring communication services for intrusion, commercial fire ...

The Aesthetic Society proudly announced the election of Tracy Pfeifer, MD, MS, as its new President during The Aesthetic MEET 2025, the premier event in aesthetic plastic surgery. A highly respected ...

Innovation Center Ltd. has led to the discovery of new leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of cancer, leprosy, tuberculosis, colitis, ...

Denali has been working on small-molecule compounds capable of crossing the blood-brain barrier and Biogen has bought a licence to co-develop and co-market compounds known as LRRK2 inhibitors in ...

Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are working on an LRRK2 inhibitor in Parkinson's, both hoping to show that the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#LRRK2--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and ...